nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.07.2006 | Original paper

α_vβ₃-integrin imaging: a new approach to characterise angiogenesis?

verfasst von: Roland Haubner

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Sonderheft 1/2006

Einloggen, um Zugang zu erhalten

Abstract

Overview

The field of angiogenesis research is one of the most rapidly growing biomedical disciplines. Great efforts are being made to develop anti-angiogenesis drugs for treatment of cancer as well as non-oncological diseases. Thus, imaging techniques allowing non-invasive monitoring of corresponding molecular processes will be of great interest. One target structure involved in the angiogenic process is the integrin α_vβ₃, which mediates the migration of activated endothelial cells during vessel formation.

Materials and methods

A variety of radiolabelled RGD peptides have been introduced for monitoring of α_vβ₃ expression using nuclear medicine tracer techniques.

Objectives

This review discusses tracer development and highlights some strategies for tracer optimisation. It summarises the preclinical and clinical data and discusses the potential of this class of tracer to characterise angiogenesis.

Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407:249–57PubMedCrossRef

Storgard CM, Stupack DG, Jonczyk A, Goodman SL, Fox RI, Cheresh DA. Decreased angiogenesis and arthritic disease in rabbits treated with an α_vβ₃ antagonist. J Clin Invest 1999;103:47–54PubMedCrossRef

Creamer D, Sullivan D, Bicknell R, Barker J. Angiogenesis in psoriasis. Angiogenesis 2002;5:231–6PubMedCrossRef

Bishop GG, McPherson JA, Sanders JM, Hesselbacher SE, Feldman MJ, McNamara CA, et al. Selective α_vβ₃-receptor blockade reduces macrophage infiltration and restenosis after balloon angioplasty in the atherosclerotic rabbit. Circulation 2001;103:1906–11PubMed

Chavakis E, Riecke B, Lin J, Linn T, Bretzel RG, Preissner KT, Brownlee M, Hammes HP. Kinetics of integrin expression in the mouse model of proliferative retinopathy and success of secondary intervention with cyclic RGD peptides. Diabetologia 2002;45:262–7PubMedCrossRef

Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29:15–8PubMed

Carmeliet P. Angiogenesis in health and disease. Nat Med 2003;9:653–60PubMedCrossRef

Ellis LM, Liu W, Fan F, Jung YD, Reinmuth N, Stoeltzing O, et al. Synopsis of angiogenesis inhibitors in oncology. Oncology 2002;16:14–22PubMed

Hagedorn M, Bikfalvi A. Target molecules for anti-angiogenic therapy: from basic research to clinical trials. Crit Rev Oncol Hematol 2000;34:89–110PubMedCrossRef

10.

Kuwano M, Fukushi J, Okamoto M, Nishie A, Goto H, Ishibashi T, et al. Angiogenesis factors. Intern Med 2001;40:565–72PubMedCrossRef

11.

Rundhaug JE. Matrix metalloproteinases and angiogenesis. J Cell Mol Med 2005;9:267–85PubMedCrossRef

12.

Eliceiri BP, Cheresh DA. Role of alpha v integrins during angiogenesis. Cancer J Sci Am 2000;6:S245–9

13.

Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000;407:242–8PubMedCrossRef

14.

Mitjans F, Meyer T, Fittschen C, Goodman S, Jonczyk A, Marshall JF, et al. In vivo therapy of malignant melanoma by means of antagonists of alphav integrins. Int J Cancer 2000;87:716–23PubMedCrossRef

15.

Patel SR, Jenkins J, Papadopolous N, Burgess MA, Plager C, Gutterman J, et al. Pilot study of vitaxin—an angiogenesis inhibitor-in patients with advanced leiomyosarcomas. Cancer 2001;92:1347–8PubMedCrossRef

16.

Hynes RO. A reevaluation of integrins as regulators of angiogenesis. Nat Med 2002;8:918–21PubMedCrossRef

17.

Matter A. Tumor angiogenesis as a therapeutic target. Drug Discov Today 2001;6:1005–24PubMedCrossRef

18.

Longo R, Sarmiento R, Fanelli M, Capaccetti B, Gattuso D, Gasparini G. Anti-angiogenic therapy: rationale, challenges and clinical studies. Angiogenesis 2002;5:237–56PubMedCrossRef

19.

Smith JW. Cilengitide Merck. Curr Opin Investig Drugs 2003;4:741–5PubMed

20.

Raguse JD, Gath HJ, Bier J, Riess H, Oettle H. Cilengitide (EMD 121974) arrests the growth of a heavily pretreated highly vascularised head and neck tumour. Oral Oncol 2004;40:228–30PubMedCrossRef

21.

Ruoslahti E, Pierschbacher MD. New perspectives in cell adhesion: RGD and integrins. Science 1987;238:491–7PubMedCrossRef

22.

Haubner R, Finsinger D, Kessler H. Stereoisomeric peptide libraries and peptidomimetics for designing selective inhibitors of the α_vβ₃ integrin for a new cancer therapy. Angew Chem Int Ed Engl 1997;36:1374–89CrossRef

23.

Aumailley M, Gurrath M, Muller G, Calvete J, Timpl R, Kessler H. Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. FEBS Lett 1991;291:50–4PubMedCrossRef

24.

Haubner R, Wester HJ. Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies. Curr Pharm Des 2004;10:1439–55PubMedCrossRef

25.

Haubner R, Wester HJ, Reuning U, Senekowitsch-Schmidtke R, Diefenbach B, Kessler H, et al. Radiolabeled α_vβ₃ integrin antagonists: a new class of tracers for tumor targeting. J Nucl Med 1999;40:1061–71PubMed

26.

Haubner R, Wester HJ, Weber WA, Mang C, Ziegler SI, Goodman SL, et al. Noninvasive imaging of α_vβ₃ integrin expression using ¹⁸F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 2001;61:1781–5PubMed

27.

Haubner R, Wester HJ, Burkhart F, Senekowitsch-Schmidtke R, Weber W, Goodman SL, et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med 2001;42:326–36PubMed

28.

Haubner R, Kuhnast B, Mang C, Weber WA, Kessler H, Wester HJ, et al. [¹⁸F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem 2004;15:61–9PubMedCrossRef

29.

Haubner R, Kuhnast B, Wester HJ, Weber WA, Huber R, Senekowitsch-Schmidtke R, et al. [F-18]-RGD-peptides conjugated with hydrophilic tetrapeptides for the noninvasive determination of the α_vβ₃ integrin. J Nucl Med 2002;43 (Suppl):89P

30.

Harris JM, Martin NE, Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 2001;40:539–51PubMedCrossRef

31.

Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2003;2:214–21PubMedCrossRef

32.

Chen X, Park R, Shahinian AH, Bading JR, Conti PS. Pharmacokinetics and tumor retention of ¹²⁵I-labeled RGD peptide are improved by PEGylation. Nucl Med Biol 2004;31:11–9PubMedCrossRef

33.

Chen X, Park R, Hou Y, Khankaldyyan V, Gonzales-Gomez I, Tohme M, et al. MicroPET imaging of brain tumor angiogenesis with ¹⁸F-labeled PEGylated RGD peptide. Eur J Nucl Med Mol Imaging 2004;31:1081–9PubMedCrossRef

34.

Chen X, Hou Y, Tohme M, Park R, Khankaldyyan V, Gonzales-Gomez I, et al. Pegylated Arg-Gly-Asp peptide: ⁶⁴Cu labeling and PET imaging of brain tumor α_vβ₃-integrin expression. J Nucl Med 2004;45:1776–83PubMed

35.

van Hagen PM, Breeman WA, Bernard HF, Schaar M, Mooij CM, Srinivasan A, et al. Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy. Int J Cancer 2000;90:186–98PubMedCrossRef

36.

Wang W, McMurray JS, Wu Q, Campbell ML, Li C. Convenient solid-phase synthesis of diethylenetriaminepenta-acetic acid (DTPA)-conjugated cyclic RGD peptide analogues. Cancer Biother Radiopharm 2005;20:547–56PubMedCrossRef

37.

Haubner R, Bruchertseifer F, Bock M, Kessler H, Schwaiger M, Wester HJ. Synthesis and biological evaluation of a ^99mTc-labelled cyclic RGD peptide for imaging the α_vβ₃ expression. Nuklearmedizin 2004;43:26–32PubMed

38.

Chen X, Park R, Tohme M, Shahinian AH, Bading JR, Conti PS. MicroPET and autoradiographic imaging of breast cancer αv-integrin expression using ¹⁸F- and ⁶⁴Cu-labeled RGD peptide. Bioconjug Chem 2004;15:41–9PubMedCrossRef

39.

Assa-Munt N, Jia X, Laakkonen P, Ruoslahti E. Solution structures and integrin binding activities of an RGD peptide with two isomers. Biochemistry 2001;40:2373–8PubMedCrossRef

40.

Su ZF, Liu G, Gupta S, Zhu Z, Rusckowski M, Hnatowich DJ. In vitro and in vivo evaluation of a technetium-99m-labeled cyclic RGD peptide as a specific marker of α_vβ₃ integrin for tumor imaging. Bioconjug Chem 2002;13:561–70PubMedCrossRef

41.

Su ZF, He J, Rusckowski M, Hnatowich DJ. In vitro cell studies of technetium-99m labeled RGD-HYNIC peptide, a comparison of tricine and EDDA as co-ligands. Nucl Med Biol 2003;30:141–9PubMedCrossRef

42.

Janssen ML, Oyen WJ, Dijkgraaf I, Massuger LF, Frielink C, Edwards DS, et al. Tumor targeting with radiolabeled α_vβ₃ integrin binding peptides in a nude mouse model. Cancer Res 2002;62:6146–51PubMed

43.

Janssen MLH, Oyen WJG, Massuger LFAG, Frielink C, Dijkgraaf I, Edwards DS, et al. Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor imaging. Cancer Biother Radiopharm 2002;17:641–6PubMedCrossRef

44.

Thumshirn G, Hersel U, Goodman SL, Kessler H. Multimeric cyclic RGD peptides as potential tools for tumor targeting: solid-phase peptide synthesis and chemoselective oxime ligation. Chemistry 2003;9:2717–25PubMedCrossRef

45.

Poethko T, Schottelius M, Thumshirn G, Hersel U, Herz M, Henriksen G, et al. Two-step methodology for high-yield routine radiohalogenation of peptides: ¹⁸F-labeled RGD and octreotide analogs. J Nucl Med 2004;45:892–902PubMed

46.

Poethko T, Schottelius M, Thumshirn G, Herz M, Haubner R, Henriksen G, et al. Chemoselective pre-conjugate radiohalogenation of unprotected mono- and multimeric peptides via oxime formation. Radiochimica Acta 2004;92:317–27CrossRef

47.

Chen X, Tohme M, Park R, Hou Y, Bading JR, Conti PS. Micro-PET imaging of α_vβ₃-integrin expression with ¹⁸F-labeled dimeric RGD peptide. Mol Imaging 2004;3:96–104PubMedCrossRef

48.

Zhang X, Xiong Z, Wu Y, Cai W, Tseng JR, Gambhir SS, Chen X. Quantitative PET imaging of tumor integrin α_vβ₃ expression with ¹⁸F-FRGD2. J Nucl Med 2006;47:113–21PubMed

49.

Chen X, Liu S, Hou Y, Tohme M, Park R, Bading JR, et al. MicroPET imaging of breast cancer alphav-integrin expression with ⁶⁴Cu-labeled dimeric RGD peptides. Mol Imaging Biol 2004;6:350–9PubMedCrossRef

50.

Wu Y, Zhang X, Xiong Z, Cheng Z, Fisher DR, Liu S, et al. MicroPET imaging of glioma integrin α_vβ₃ expression using ⁶⁴Cu-labeled tetrameric RGD peptide. J Nucl Med 2005;46:1707–18PubMed

51.

Felding-Habermann B, Mueller BM, Romerdahl CA, Cheresh DA. Involvement of integrin αv gene expression in human melanoma tumorigenicity. J Clin Invest 1992;89:2018–22PubMedCrossRef

52.

Haubner R, Weber WA, Beer AJ, Vabuliene E, Reim D, Sarbia M, et al. Noninvasive visualization of the activated α_vβ₃ integrin in cancer patients by positron emission tomography and [¹⁸F]Galacto-RGD. PLoS Med 2005;2:29CrossRef

53.

Myoken Y, Kayada Y, Okamoto T, Kan M, Sato GH, Sato JD. Vascular endothelial cell growth factor (VEGF) produced by A-431 human epidermoid carcimoma cells and identification of VEGF membrane binding sites. Proc Natl Acad Sci U S A 1991;88:5818–23CrossRef

54.

Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 1999;284:808–12PubMedCrossRef

55.

Pichler B, Braumueller H, Haubner R, Sakrauski AK, Kneilling M, Senekowitsch-Schmidtke R, et al. Monitoring of cellular immunotherapy in RIP1-Tag2 transgenic mice with radiolabeled RGD-peptides. J Nucl Med 2002;43:122P

56.

Pichler BJ, Kneilling M, Haubner R, Braumuller H, Schwaiger M, Rocken M, et al. Imaging of delayed-type hypersensitivity reaction by PET and ¹⁸F-Galacto-RGD. J Nucl Med 2005;46:184–9PubMed

57.

Beer AJ, Haubner R, Goebel M, Luderschmidt S, Spilker ME, Wester HJ, et al. Biodistribution and pharmacokinetics of the α_vβ₃-selective tracer ¹⁸F-Galacto-RGD in cancer patients. J Nucl Med 2005;46:1333–41PubMed

58.

Beer AJ, Haubner R, Wolf I, Goebel M, Luderschmidt S, Niemeyer M, et al. PET-based dosimetry in man of [¹⁸F]Galacto-RGD, a new radiotracer for imaging of α_vβ₃ expression. J Nucl Med 2006;47:763–9PubMed

59.

Beer AJ, Haubner R, Sarbia M, Goebel M, Luderschmidt S, Grosu AL, Schnell O, Niemeyer M, Kessler H, Wester HJ, Weber WA, Schwaiger M. Positron emission tomography using [¹⁸F]Galacto-RGD identifies the level of integrin α_vβ₃ expresssion in man. Clin Cancer Res 2006; in press

60.

Gasparini G, Barbareschi M, Boracchi P, Verderio P, Caffo O, Meli S, et al. Tumor angiogenesis predicts clinical outcome of node-positive breast cancer patients treated with adjuvant hormone therapy or chemotherapy. Cancer J Sci Am 1995;1:131PubMed

61.

Ogawa M, Hatano K, Oishi S, Kawasumi Y, Fujii N, Kawaguchi M, et al. Direct electrophilic radiofluorination of a cyclic RGD peptide for in vivo α_vβ₃ integrin related tumor imagin. Nucl Med Biol 2003;30:1–9PubMedCrossRef

62.

Bock M, Bruchertseifer F, Haubner R, Senekowitsch-Schmidtke R, Kessler H, Schwaiger M, Wester HJ. ^99mTc-, ¹⁸⁸Re- and ⁹⁰Y-labeled α_vβ₃ antagonists: promising tracer for tumor-induced angiogenesis. J Nucl Med 2000;41(suppl):41P

Titel: αvβ3-integrin imaging: a new approach to characterise angiogenesis?
verfasst von: Roland Haubner
Publikationsdatum: 01.07.2006
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe Sonderheft 1/2006
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-006-0136-0

Springer Medizin

Abstract

Overview

Materials and methods

Objectives

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 1/2006

Monitoring chemotherapy and radiotherapy of solid tumors

Use of FDG-PET to monitor response to chemotherapy and radiotherapy in patients with lymphomas

Hypoxia imaging-directed radiation treatment planning

Imaging biomarkers as surrogate endpoints for drug development

Biological imaging for selecting and monitoring cancer therapy; a pathway to individualised therapy

How should we analyse FDG PET studies for monitoring tumour response?